Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
By
MedTech Outlook | Tuesday, April 27, 2021
The abstracts cover a wide range of topics, from how AI can be used to monitor the progression of GA lesions to new safety
FREMONT, CA: Apellis Pharmaceuticals, a multinational biopharmaceutical company and pioneer in focused C3 therapies, announced that ten abstracts have been approved for presentation at the virtual Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will take place May 1-7, 2021. These abstracts cover a wide range of topics, from how AI can be used to monitor the progression of GA lesions to new safety and efficacy evidence for pegcetacoplan, an investigational targeted C3 therapy for GA.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“New imaging approaches, AI-based technologies, and ultimately the development of new medicines will transform the treatment of geographic atrophy,” said Federico Grossi, M.D., Ph.D., Chief Medical Officer of Apellis. “Our data across these disciplines at ARVO exemplify our leadership in the retina and underscore the potential of pegcetacoplan to become the first medicine for people living with GA, a relentless disabling disease.”
Studies evaluating the use of AI to recognize, track, and forecast the growth of GA lesions are among the five oral presentations. The studies were carried out in collaboration with the Ophthalmic Image Analysis (OPTIMA) group at the Medical University of Vienna, one of the world’s leading data analysis laboratories for retinal diseases, on retinal scans from the positive Phase 2 FILLY sample, which showed that pegcetacoplan decreased the growth rate of GA lesions.
“Our collaboration showed that AI can distinctly and reliably measure GA disease progression,” said Ursula Schmidt-Erfurth, M.D., professor and chair of the Department of Ophthalmology at the University Eye Hospital, Vienna, Austria. “The results support the use of AI analytics as an ideal tool to evaluate disease activity as well as therapeutic efficacy in GA.”
The oral presentations from the AI collaboration include:
• AI-Based Quantification of Photoreceptor Maintenance in the Treatment of Geographic Atrophy Secondary to AMD in the FILLY Trial May 2, 11:15 a.m. - 12:45 p.m. ET
• SD-OCT Based Analysis of Treatment Effects on Geographic Atrophy Secondary to AMD in the FILLY Trial of Pegcetacoplan May 2, 11:15 a.m. - 12:45 p.m. ET
• Monitoring GA Lesion Size on Optical Coherence Tomography (OCT) Using Automated Deep Learning-Based Image Segmentation in the FILLY Phase 2 Clinical Trial May 2, 11:15 a.m. - 12:45 p.m. ET
• Topographic Effects on AI Quantified Regional Progression in the FILLY Trial of Pegcetacoplan for Treatment of Geographic Atrophy Secondary to AMD May 3, 4:30 p.m. - 6:00 p.m. ET
• Predictive Identification of the Fastest Progressing Geographic Atrophy Lesions Based on Deep Learning in the Phase 2 FILLY Clinical Trial of Pegcetacoplan May 3, 4:30 p.m - 6:00 p.m. ET
Apellis abstracts regarding the safety and efficacy of pegcetacoplan and unmet need in GA include:
• A Phase 1b Multi-Center, Open-Label, Single-Arm Safety Study of Intravitreal Pegcetacoplan Supporting the Phase 3 DERBY and OAKS Studies for Geographic Atrophy: A Solution to Tarmac Delay Poster Abstract May 1, 10:15 a.m. - 12:00 p.m. ET
• Safety of Intravitreal Pegcetacoplan in Patients with Neovascular Age-Related Macular Degeneration Receiving Anti-VEGF Therapy Poster Abstract May 3, 4:30 p.m. - 6:15 p.m. ET
• Evaluation of Geographic Atrophy Secondary to Age-Related Macular Degeneration in Clinical Practice: Analysis of the AAO IRIS Registry Poster Abstract May 4, 2:15 p.m. - 4:00 p.m. ET
• Ocular Distribution of Pegcetacoplan in Rabbits Following a Single Intravitreal Injection. Poster Abstract May 5, 9:00 - 10:45 a.m. ET
• Impact of Pegcetacoplan on Progression of Nascent Atrophy in Age-Related Macular Degeneration (AMD) Paper Abstract May 7, 4:15 p.m. - 5:45 p.m. ET
More in News
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
